Posted by Michael Wonder on 07 Nov 2024
PHARMAC publishes agenda for the November 2024 PTAC meeting
6 November 2024 - PHARMAC has published the agenda for the upcoming 14-15 November 2024 PTAC meeting.
The PTAC will consider funding applications for the following medicines:
- Ocrelizumab (Ocrevus) - multiple sclerosis
- Testosterone (AndroFeme 1) - hypoactive sexual desire dysfunction
- Tezepelumab (Tezspire) - asthma
- Benralizumab (Fasenra) and mepolizumab (Nucala) - asthma (restriction change)
- Atezolizumab (Tecentriq) - breast cancer
